ACME Laboratories's ROE % for the quarter that ended in Mar. 2026 was 10.10%. ACME Laboratories's PB Ratio for the quarter that ended in Mar. 2026 was 0.57.
ACME Laboratories's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 17.72%.
ACME Laboratories ROE % Adjusted to Book Value Related Terms
ACME Laboratories ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories ROE % Adjusted to Book Value Chart
DHA:ACMELAB vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 17.72% mean?
ACME Laboratories (DHA:ACMELAB) has a ROE % Adjusted to Book Value of 17.72% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ACME Laboratories and its competitors.
Is ACME Laboratories' ROE % Adjusted to Book Value too high?
ACME Laboratories' current ROE % Adjusted to Book Value is 17.72%. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' ROE % Adjusted to Book Value compare to ZTS and UTHR?
ACME Laboratories' ROE % Adjusted to Book Value of 17.72% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ACME Laboratories and its competitors. ACME Laboratories's current ROE % Adjusted to Book Value is 17.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.14, compared to a current price of BDT82.60 — trading 34% below its estimated fair value. The current ROE % Adjusted to Book Value is 17.72%. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current ROE % Adjusted to Book Value is 17.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.60 is trading 34% below its estimated GF Value™ of BDT125.14.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
ROE % Adjusted to Book Value: 17.72%
GF Value™: BDT125.14 vs. price of BDT82.60 (34% below fair value)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
